(Q73308741)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12711359%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

review article

1 reference

title

Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12711359%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

Shimon Slavin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12711359%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Shoshana Morecki

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12711359%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Lola Weiss

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12711359%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Reuven Or

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12711359%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 May 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12711359%20AND%20SRC:MED&resulttype=core&format=json

Critical Reviews in Oncology Hematology

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12711359%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12711359%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12711359%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

139-163

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12711359%20AND%20SRC:MED&resulttype=core&format=json

Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Kettering Award Lecture. The role of marrow transplantation in the eradication of malignant disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Possibility of graft-vs-leukemia determinants independent of the major histocompatibility complex in allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Transplantation of allogeneic bone marrow without graft-versus-host disease using total lymphoid irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-alpha 2a.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

The role of purified CD8+ T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Spontaneous murine B-cell leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

The CAMPATH-1 antigen (CDw52)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Mini-allografts: ongoing trials in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Bone marrow transplantation from a cadaveric donor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi anemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Total lymphoid irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Mixed allogeneic chimerism as an approach to transplantation tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Nonmyeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900108-7

7 January 2021

10.1016/S1040-8428(02)00108-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12711359%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference